According to data from eight studies being presented at The International Liver Congress 2017 in Amsterdam, The Netherlands, there remains continued debate on whether patients are at risk of ...
A study published in 2016 raised concerns that patients with liver cancer related to hepatitis C virus (HCV) may have a higher risk for recurrence if they are treated with direct-acting antiviral (DAA ...
Recently published data showed no association between direct-acting antiviral therapy and an increased risk for hepatocellular carcinoma recurrence among liver transplantation candidates with ...
Credit: Shutterstock. Direct-acting antiviral therapy is not associated with increased overall or early hepatocellular carcinoma recurrence among patients with a previous complete response to HCC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback